QuidelOrtho Corp (QDEL): Results of Operations and Financial Condition
QuidelOrtho Corp (QDEL) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 qdel6282026ex991earningsre.htm EX-99.1 Document Exhibit 99.1 QuidelOrtho Reports Second Quarter 2026 Financial Results ― Total revenue grew 3% reported and 2% constant currency, primarily driven by Labs and Point of Care growth― ― Excluding China, total revenue grew 6%
How this was made
The 30-second read
Why it matters
The key tradable items are the updated revenue, adjusted EBITDA, and adjusted EPS ranges, plus the explicit withdrawal of free cash flow guidance. The company links the reset to China demand headwinds from proposed IVD pricing changes and a softer global respiratory environment, while noting ex-China growth strength.
Market read
Traders can update valuation and positioning based on the guidance cut and the new cash-conversion uncertainty signaled by the FCF withdrawal.
What to watch
The company attributes China weakness to proposed IVD pricing guideline changes and also withdraws FCF guidance due to working-capital impacts, so investors should separate demand softness from cash timing effects.
Background
This is QuidelOrtho’s SEC Form 8-K reporting Q2 2026 results and updated full-year 2026 financial guidance, including a decision to withdraw free cash flow guidance.
Ticker impact
QuidelOrtho reported Q2 revenue of $631M and revised full-year 2026 guidance, including withdrawing free cash flow guidance amid China headwinds.
Near-term volatility likely as investors reprice 2026 revenue and EBITDA expectations and focus on working-capital driven cash uncertainty.
The filing discloses specific updated ranges for total revenue, adjusted EBITDA, adjusted EPS, and explicitly withdraws free cash flow guidance, tied to China demand headwinds and working-capital impacts.
Market effects
Diagnostic/IVD peers may see read-across on China pricing pressure and respiratory demand softness, but the impact is company-specific.
China weakness is explicitly cited as a driver of the guidance reset, highlighting regional demand sensitivity.
Limited broader macro relevance; primarily a single-company earnings and cash-conversion signal.
Counterpoint
Ex-China revenue growth (Labs +9%, Immunohematology +5%) and improved adjusted EBITDA margin could support a faster-than-expected normalization if China stabilizes.
Key entities
- companyQuidelOrtho Corporation
Nasdaq-listed diagnostics provider reporting Q2 results and updating 2026 guidance, citing China headwinds and withdrawing free cash flow guidance.
- executiveBrian J. Blaser
CEO who commented on Q2 performance, China demand headwinds, and the guidance revisions.
